Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: blankmind who wrote (682)	11/17/1999 3:05:00 PM
From: William Partmann	Read Replies (1) \| Respond to of 10345

Elan Appoints Dr. Ivan Lieberburg as Executive Vice President and Chief Scientific and Medical Officer DUBLIN, Ireland, Nov. 17 /PRNewswire/ -- Elan Corporation, plc (NYSE: ELN - news; ''Elan'') is pleased to announce the appointment of Ivan Lieberburg, Ph.D., MD to Executive Vice President and Chief Scientific and Medical Officer of the Corporation, reporting to the Chairman and CEO, Mr. Donal Geaney. Dr. Lieberburg has been an active biomedical researcher for over 25 years, having authored over 100 research publications. He received an AB in biology from Cornell University, a Ph.D. from The Rockefeller University and an MD from the University of Miami. He completed post-doctoral training at The Rockefeller University and the University of California, San Francisco. He completed his clinical training also at UCSF, where he is currently a Clinical Professor of Medicine. Dr. Lieberburg has been honoured with a number of prestigious awards including Rockefeller University Fellow, Hartford Foundation Scholar, McKnight Foundation Fellow in Neuroscience and Public Health Service Scholar. He is board certified by the American College of Physicians in Internal Medicine and Endocrinology and Metabolism. Prior to joining Elan in 1987, Dr. Lieberburg held faculty positions at Albert Einstein College of Medicine and Mt Sinai School of Medicine in New York. At Elan, Dr. Lieberburg has held a number of key research posts, most recently as Senior Vice President of Research at Elan Pharmaceuticals. Under his guidance Elan has taken a leading position in research and drug discovery in the neurosciences. In his new position Dr. Lieberburg will join Elan's Corporate Management Committee and will advise the Chairman, the Board of Directors and senior management on scientific and medical issues. Elan is a leading worldwide specialty pharmaceutical company headquartered in Ireland, with its principal research, development, manufacturing and marketing facilities located in Ireland, the United States and Israel. Elan shares trade on the New York, London and Dublin Stock Exchanges. SOURCE: Elan Corporation, plc